Established Cardiovascular Disease: Open Controversies in the Field

Why Controversies Persist in a Well-Studied Disease

Cardiovascular disease is the leading cause of death globally, accounting for an estimated 17.9 million deaths per year according to the World Health Organization [1]. Decades of randomized trials have established lipid-lowering, antiplatelet therapy, and blood-pressure control as the pillars of secondary prevention. Yet significant clinical disagreement continues on at least six questions: how aggressively to lower LDL-C, whether to add anti-inflammatory therapy, when to stop or continue dual antiplatelet therapy, what role newer agents such as PCSK9 inhibitors and GLP-1 receptor agonists should play, how to handle aspirin in an era of better anticoagulants, and how to quantify and target residual risk.

These debates are not merely academic. Guideline committees at the American College of Cardiology, the American Heart Association, and the European Society of Cardiology have published conflicting or evolving class recommendations on several of these topics over the past five years [2]. Patients with established CVD face real trade-offs between bleeding risk, pill burden, cost, and incremental cardiovascular benefit.

Why Residual Risk Drives the Controversy

Even when LDL-C is reduced below 70 mg/dL with high-intensity statin therapy, roughly 20% of patients experience a recurrent major adverse cardiovascular event (MACE) within five years [3]. That "residual risk" has become the organizing concept for most modern controversies: which additional pathways (inflammation, triglycerides, thrombosis, plaque biology) should be targeted, in whom, and at what cost?

Controversy 1: How Low Should LDL-C Go?

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol established an LDL-C goal of <70 mg/dL for patients with established CVD on maximally tolerated statin therapy, with a Class IIa recommendation to consider adding ezetimibe if that target is not met [4]. The 2022 update moved further, designating "very high-risk" secondary-prevention patients as targets for <55 mg/dL when PCSK9 inhibitor therapy is considered.

The PCSK9 Inhibitor Evidence

FOURIER (N=27,564) demonstrated that evolocumab added to statin therapy reduced LDL-C by 59% (from a median of 92 mg/dL to 30 mg/dL) and cut the primary composite endpoint by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [5]. ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced MACE by 15% (HR 0.85, 95% CI 0.78 to 0.93) after acute coronary syndrome [6]. These trials firmly established that LDL-C levels well below historical targets produce additional benefit.

The Counter-Argument: Diminishing Returns and Cost

Critics note that absolute risk reductions in FOURIER were modest (2.2 percentage points over 2.2 years), and annual PCSK9 inhibitor costs exceeded $14,000 before rebates became widespread [7]. A 2022 cost-effectiveness analysis in the Journal of the American College of Cardiology estimated a cost per quality-adjusted life-year gained of approximately $450,000 at list price, far above the conventional $100,000, $150,000 willingness-to-pay threshold [8]. Some cardiologists argue that universal <55 mg/dL targets are aspirational without broader drug pricing reform.

The "LDL Hypothesis" Is Not Fully Settled at Extremes

Mendelian randomization data support lifelong low LDL-C as protective [9]. Still, no randomized trial has specifically enrolled patients to a <40 mg/dL LDL-C target arm and followed them for hard outcomes over a decade. Observational data showing J-curve relationships remain methodologically disputed.

Controversy 2: Targeting Residual Inflammatory Risk

The CANTOS trial (N=10,061) was the first to show that canakinumab, a monoclonal antibody targeting interleukin-1 beta, reduced recurrent MACE by 15% (HR 0.85, 95% CI 0.74 to 0.98) in post-MI patients with elevated high-sensitivity C-reactive protein (hsCRP >2 mg/L), independent of lipid-lowering [10]. This result shifted debate: inflammation, not just lipids, may be a modifiable causal risk factor.

What CANTOS Did Not Resolve

Canakinumab is not approved for cardiovascular indications and carries a significant infection risk. The 2024 ACC/AHA guidelines do not recommend routine hsCRP testing or anti-IL-1 therapy outside of specific high-risk populations such as those with recurrent events despite optimal LDL-C control [2]. The question of which anti-inflammatory agent, at what dose, in which patient subgroup, remains unanswered.

Colchicine: A More Accessible Option

COLCOT (N=4,745) showed colchicine 0.5 mg daily started within 30 days of MI reduced the primary composite endpoint (cardiovascular death, cardiac arrest, MI, stroke, or urgent hospitalization for angina) by 23% (HR 0.77, 95% CI 0.61 to 0.96) [11]. LoDoCo2 (N=5,522) confirmed colchicine 0.5 mg daily reduced cardiovascular events by 31% in chronic coronary disease (HR 0.69, 95% CI 0.57 to 0.83) [12]. Canada and Australia have incorporated colchicine into their post-MI guidelines. The United States has not yet made it a Class I recommendation, partly because of lingering questions about non-cardiovascular mortality signals in LoDoCo2.

hsCRP as a Treatment Target: Still Debated

Some cardiologists now advocate routinely measuring hsCRP after optimal lipid control to identify candidates for anti-inflammatory therapy. Others argue that biomarker-guided prescribing is premature without a trial showing that treat-to-hsCRP-target improves outcomes better than treat-to-LDL-target alone. The ESC 2021 Prevention Guidelines acknowledge hsCRP as a risk-modifier but stop short of mandating measurement [13].

Controversy 3: Aspirin in Secondary Prevention, Still the Standard?

Aspirin's role in primary prevention has collapsed. The ASPREE (N=19,114), ARRIVE (N=12,546), and ASCEND (N=15,480) trials collectively showed that aspirin does not reduce MACE in low-to-moderate-risk adults without prior CVD and increases gastrointestinal bleeding risk [14]. The USPSTF in 2022 issued a Grade D recommendation against aspirin initiation for primary prevention in adults 60 years and older [15].

Secondary prevention is a different matter. Aspirin 75 to 100 mg daily remains a Class I recommendation in the 2021 ACC/AHA Chest Pain Guidelines and the 2023 AHA/ACC Guidelines for Coronary Artery Disease for patients with established CVD [2]. No large randomized trial has tested aspirin withdrawal against placebo in stable secondary-prevention patients already on modern therapy.

Dual Antiplatelet Therapy Duration: The Real Battleground

After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is standard. How long DAPT should continue is hotly debated. The DAPT study (N=9,961) showed 30 months of DAPT reduced stent thrombosis and MI versus 12 months but increased bleeding [16]. TWILIGHT (N=9,006) showed that dropping aspirin after 3 months and continuing ticagrelor monotherapy reduced BARC 2/3/5 bleeding by 44% without increasing ischemic events [17].

Ticagrelor or Clopidogrel After the First Year?

PEGASUS-TIMI 54 (N=21,162) showed ticagrelor 60 mg twice daily added to aspirin reduced MACE by 16% in patients 1 to 3 years post-MI versus placebo but increased TIMI major bleeding (2.3% vs. 1.1%) [18]. The net-clinical-benefit calculation differs by patient bleeding risk, age, renal function, and prior stroke, areas where no definitive consensus exists.

Controversy 4: GLP-1 Receptor Agonists in Established CVD Without Diabetes

GLP-1 receptor agonists were initially approved for type 2 diabetes, but cardiovascular outcome trials quickly identified strong cardiovascular signals. LEADER (N=9,340) showed liraglutide reduced 3-point MACE by 13% (HR 0.87, 95% CI 0.78 to 0.97) versus placebo in patients with type 2 diabetes and high cardiovascular risk [19]. SUSTAIN-6 (N=3,297) showed semaglutide 0.5 mg or 1.0 mg weekly reduced MACE by 26% (HR 0.74, 95% CI 0.58 to 0.95) [20].

The Non-Diabetic CVD Question

SELECT (N=17,604), published in 2023, enrolled patients with established CVD and overweight or obesity (BMI >27) but without diabetes. Semaglutide 2.4 mg weekly reduced MACE by 20% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) over a mean follow-up of 33.3 months [21]. This was the first trial to show a GLP-1 agonist reduces cardiovascular events in a non-diabetic CVD population. The FDA approved semaglutide 2.4 mg for cardiovascular risk reduction in obese or overweight adults with established CVD in March 2024 [22].

Where the Debate Stands

Despite SELECT, controversy remains on several points. First, the mechanism driving cardiovascular benefit is unclear: weight loss, glucose lowering, direct cardiac effects, and inflammation reduction all likely contribute in ways that remain unquantified [23]. Second, cost and access are barriers: semaglutide 2.4 mg (Wegovy) carries a list price exceeding $1,300 per month, and insurance coverage for cardiovascular indications is still evolving. Third, some cardiologists question whether equivalent benefit could be achieved through intensive lifestyle intervention in the same population.

A Practical Prescribing Framework for CVD Patients

Cardiologists currently lack a consensus algorithm for GLP-1 use in non-diabetic CVD patients. Based on SELECT enrollment criteria and the approved label, reasonable candidates include patients with BMI >27, established atherosclerotic CVD (prior MI, stroke, or symptomatic PAD), and no contraindications (personal or family history of medullary thyroid carcinoma, MEN2, or pancreatitis). Clinicians should document cardiovascular indication explicitly in the chart to support insurance authorization, since obesity coding alone is frequently denied.

Controversy 5: Omega-3 Fatty Acids, Benefit or Harm?

The omega-3 story is one of the most whiplash-inducing in cardiovascular medicine. Early meta-analyses suggested benefit. ASCEND-NMA (a pre-specified meta-analysis) and ORIGIN (N=12,537) found no benefit from omega-3 supplementation in people with diabetes or dysglycemia [24]. Then REDUCE-IT (N=8,179) showed icosapentaenoic acid (EPA) ethyl esters (Vascepa) 4 g/day reduced MACE by 25% (HR 0.75, 95% CI 0.68 to 0.83) in statin-treated patients with elevated triglycerides [25].

The Mineral Oil Placebo Problem

REDUCE-IT used mineral oil as its placebo, which critics argued raised LDL-C and hsCRP in the control group, artificially inflating the apparent treatment benefit. STRENGTH (N=13,078), using a corn oil placebo and a different omega-3 formulation (EPA plus DHA), showed no significant reduction in MACE (HR 0.99, 95% CI 0.90 to 1.09) [26].

The FDA approved icosapentaenoic acid for cardiovascular risk reduction in statin-treated adults with triglycerides >150 mg/dL and established CVD or diabetes in December 2019 [27]. Whether the benefit is drug-specific (EPA only, not DHA) or placebo-artifact remains a genuine scientific dispute unresolved as of mid-2025.

Controversy 6: Polypharmacy, Adherence, and the "Deprescribing" Question

Patients with established CVD are typically prescribed five or more medications: a statin, an antiplatelet agent, an ACE inhibitor or ARB, a beta-blocker, and often ezetimibe or a PCSK9 inhibitor. Studies consistently show that up to 50% of post-MI patients have discontinued their statin by 12 months [28]. Non-adherence is not random: it tracks with pill burden, side-effect experience (real or nocebo), cost, and poor health literacy.

Statin Intolerance: Real or Perceived?

The SAMSON trial (N=60) used a blinded N-of-1 design and found that 90% of muscle symptom burden attributed to statins was in fact nocebo effect, the same patients reported similar symptoms on identical-appearing placebo tablets [29]. Yet some patients do have genuine statin myopathy, with creatine kinase elevation confirming muscle injury. Distinguishing true from perceived intolerance changes the management plan substantially: rechallenge on a different statin, dose reduction, or switching to every-other-day dosing.

Beta-Blockers Beyond 1 Year Post-MI: Challenged Evidence

The guideline-endorsed practice of continuing beta-blockers indefinitely after MI is now under direct scrutiny. ABYSS (N=3,698), presented at ESC 2024 and published in the New England Journal of Medicine, found that discontinuing beta-blockers was non-inferior to continuation for death, MI, stroke, or hospitalization over 3 years in patients with preserved left ventricular ejection fraction (LVEF >40%) who were more than 1 year post-MI [30]. This trial will likely prompt guideline revisions but has not yet changed major society recommendations as of this writing.

The Deprescribing Dilemma

An emerging school of geriatric cardiology argues that polypharmacy in patients over 75 with established CVD and multiple comorbidities causes net harm through drug interactions, fall risk, and cognitive effects that outweigh marginal cardiovascular benefit. No large randomized trial has tested systematic deprescribing in this population against standard care. The 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure acknowledges this gap but provides no quantitative thresholds for when to reduce therapy [31].

Controversy 7: Blood Pressure Targets in Secondary Prevention

SPRINT (N=9,361) showed that a systolic blood pressure target of <120 mmHg reduced cardiovascular events and death compared with <140 mmHg in high-risk patients without diabetes [32]. The 2017 ACC/AHA Blood Pressure Guidelines subsequently lowered the treatment threshold and endorsed a target below 130/80 mmHg for most patients with established CVD [33].

Who Benefits From Intensive Control?

ACCORD-BP enrolled patients with type 2 diabetes and found no significant reduction in MACE with intensive versus standard blood pressure control (HR 0.88, 95% CI 0.73 to 1.06) [34]. Patients with prior stroke represent a separate controversy: SPS3 (N=3,020) showed that a systolic target <130 mmHg reduced recurrent intracerebral hemorrhage but not overall stroke recurrence versus 130 to 149 mmHg [35].

The net result is that blood pressure targets in secondary CVD prevention are stratified by comorbidity in a way that no single guideline number captures cleanly. Clinicians must individualize based on age, kidney function, stroke subtype, and orthostatic symptoms.

Controversy 8: Sex and Gender Differences in CVD Management

Women with established CVD are less likely to receive high-intensity statin therapy, PCSK9 inhibitors, or cardiac rehabilitation referrals than men, even after adjustment for clinical factors [36]. Whether this reflects appropriate individualization or systematic under-treatment is debated.

Hormonal Therapy After CVD Events

For postmenopausal women with established CVD, the 2022 Menopause Society (formerly NAMS) position statement advises against initiating systemic hormone therapy solely for cardiovascular protection, citing the Women's Health Initiative data showing increased cardiovascular events in older women initiating conjugated equine estrogen plus medroxyprogesterone acetate [37]. The WHI hormone trial enrolled women at a mean age of 63, well past the "timing hypothesis" window, so the data may not apply to women who develop CVD in their 50s while already on HRT initiated near menopause. That debate is ongoing [38].

Pregnancy-Associated CVD Risk

A history of preeclampsia doubles lifetime risk of hypertension and increases CVD risk by approximately 2-fold [39]. Guidelines now recommend CVD screening and risk-factor management in women with prior adverse pregnancy outcomes, but the optimal follow-up interval and specific screening protocol remain undefined [40].